Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
Phase 2 Completed
41 enrolled 8 charts
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
37 enrolled
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Phase 1 Completed
17 enrolled
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction
Phase 2 Completed
37 enrolled
Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Phase 2 Completed
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
Phase 2 Completed
42 enrolled 8 charts
Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
Phase 2 Completed
88 enrolled
Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
Phase 1 Completed
16 enrolled
Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
Phase 2 Completed
55 enrolled
Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Phase 2 Completed
Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer
Phase 1 Completed
11 enrolled
Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
Phase 1 Completed
16 enrolled
Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma
Phase 2 Completed
175 enrolled